Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rifampicin + levofloxacin + ethambutol
- Development stage
- Unknown
- Lead developer
- Institute of Liver and Biliary Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
9RLE is a specialized anti-tubercular therapeutic regimen composed of rifampicin, levofloxacin, and ethambutol, intended for a treatment duration of nine months. This regimen was investigated by the Institute of Liver and Biliary Sciences (ILBS) in India specifically for the treatment of tuberculosis in patients with concurrent chronic liver disease (CLD), including both compensated and decompensated states. By excluding isoniazid and pyrazinamide—standard first-line agents with high hepatotoxic potential—and incorporating the fluoroquinolone levofloxacin, the 9RLE regimen aims to provide an effective treatment for *Mycobacterium tuberculosis* while reducing the risk of drug-induced liver injury in a vulnerable population. Rifampicin acts by inhibiting bacterial DNA-dependent RNA polymerase, levofloxacin targets DNA gyrase and topoisomerase IV, and ethambutol disrupts cell wall synthesis by inhibiting arabinosyl transferase.
- Other names
- Rifampicin + Levofloxacin + EthambutolRifampin + Levofloxacin + Ethambutol
02
Targets
DNA gyraseembB (Arabinosyltransferase EmbB)RNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on rifampicin + levofloxacin + ethambutol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rifampicin + levofloxacin + ethambutol.